دورية أكاديمية
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial
| العنوان: | Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial |
|---|---|
| المؤلفون: | Michelle M. Kim, Hemant Parmar, Yue Cao, Priyanka Pramanik, Matthew Schipper, James Hayman, Larry Junck, Aaron Mammoser, Jason Heth, Corey A. Carter, Arnold Oronsky, Susan J. Knox, Scott Caroen, Bryan Oronsky, Jan Scicinski, Theodore S. Lawrence, Christopher D. Lao |
| المصدر: | Translational Oncology, Vol 9, Iss 2, Pp 108-113 (2016) |
| بيانات النشر: | Elsevier, 2016. |
| سنة النشر: | 2016 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | BACKGROUND: Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with RRx-001 and whole brain radiotherapy (WBRT) without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-001 is an reactive oxygen and reactive nitrogen species (ROS/RNS)-dependent systemically nontoxic hypoxic cell radiosensitizer with vascular normalizing properties under investigation in patients with various solid tumors including those with brain metastases. SIGNIFICANCE: Metastatic melanoma to the brain is historically associated with poor outcomes and a median survival of 4 to 5 months. WBRT is a mainstay of treatment for patients with multiple brain metastases, but no significant therapeutic advances for these patients have been described in the literature. To date, candidate radiosensitizing agents have failed to demonstrate a survival benefit in patients with brain metastases, and in particular, no agent has demonstrated improved outcome in patients with metastatic melanoma. Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with novel radiosensitizing agent RRx-001 and WBRT without neurologic or systemic toxicity in the context of a phase I/II clinical trial. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1936-5233 1944-7124 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S1936523315300668; https://doaj.org/toc/1936-5233; https://doaj.org/toc/1944-7124 |
| DOI: | 10.1016/j.tranon.2015.12.003 |
| URL الوصول: | https://doaj.org/article/ac84a71275804d769d56c8fbc96deefe |
| رقم الأكسشن: | edsdoj.84a71275804d769d56c8fbc96deefe |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 19365233 19447124 |
|---|---|
| DOI: | 10.1016/j.tranon.2015.12.003 |